Dishman Pharmaceuticals & Chemicals Ltd.[Merged] - Research Center
532526 DISHMAN Group (B) BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Sep ' 16 | Mar ' 16 | Sep ' 15 | Sep ' 14 | Sep ' 13 | |
|---|---|---|---|---|---|
| Sales | 213.08 | 272.61 | 237.78 | 199.59 | 211.38 |
| Operating profit | 76.03 | 100.20 | 70.58 | 61.96 | 64.66 |
| Interest | 26.27 | 25.07 | 43.59 | 30.00 | 37.49 |
| Gross profit | 80.36 | 78.66 | 85.84 | 60.41 | 32.55 |
| EPS (Rs) | 2.86 | 4.87 | 5.93 | 3.34 | 0.80 |
Half yearly
results in details
| Sep ' 16 | Mar ' 16 | Sep ' 15 | Sep ' 14 | Sep ' 13 | |
|---|---|---|---|---|---|
| Other income | 30.60 | 3.54 | 58.84 | 28.46 | 5.38 |
| Stock adjustment | -8.62 | -0.21 | 9.07 | -25.40 | -13.71 |
| Raw material | 70.22 | 89.80 | 89.27 | 93.66 | 96.73 |
| Power and fuel | - | -16.46 | 16.46 | - | - |
| Employee expenses | 35.28 | 35.26 | 30.63 | 29.25 | 28.20 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 40.17 | 64.03 | 21.76 | 40.13 | 35.50 |
| Provisions made | - | - | - | - | - |
| Depreciation | 22.68 | 22.06 | 22.19 | 22.16 | 22.53 |
| Taxation | 11.51 | 17.31 | 15.79 | 11.30 | 3.58 |
| Net profit / loss | 46.17 | 39.30 | 47.85 | 26.96 | 6.44 |
| Extra ordinary item | - | - | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 32.28 | 16.14 | 16.14 | 16.14 | 16.14 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | 311.49 | 311.49 | 311.77 |
| Agg.of non promotoholding (%) | - | - | 38.60 | 38.60 | 38.63 |
| OPM (%) | 35.68 | 36.76 | 29.68 | 31.04 | 30.59 |
| GPM (%) | 32.98 | 28.49 | 28.94 | 26.49 | 15.02 |
| NPM (%) | 18.95 | 14.23 | 16.13 | 11.82 | 2.97 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis